Rafferty Asset Management LLC boosted its stake in shares of Celgene Corporation (NASDAQ:CELG) by 104.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,660 shares of the biopharmaceutical company’s stock after purchasing an additional 9,518 shares during the quarter. Rafferty Asset Management LLC’s holdings in Celgene Corporation were worth $2,423,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. United Bank lifted its holdings in shares of Celgene Corporation by 35.9% during the first quarter. United Bank now owns 4,793 shares of the biopharmaceutical company’s stock worth $596,000 after buying an additional 1,267 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in shares of Celgene Corporation by 1.4% during the first quarter. Mutual of America Capital Management LLC now owns 94,184 shares of the biopharmaceutical company’s stock worth $11,719,000 after buying an additional 1,334 shares in the last quarter. Meristem LLP lifted its holdings in shares of Celgene Corporation by 4.2% during the first quarter. Meristem LLP now owns 2,608 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 105 shares in the last quarter. Segment Wealth Management LLC lifted its holdings in shares of Celgene Corporation by 9.7% during the first quarter. Segment Wealth Management LLC now owns 2,577 shares of the biopharmaceutical company’s stock worth $321,000 after buying an additional 227 shares in the last quarter. Finally, Norinchukin Bank The lifted its holdings in shares of Celgene Corporation by 4.7% during the first quarter. Norinchukin Bank The now owns 90,401 shares of the biopharmaceutical company’s stock worth $11,249,000 after buying an additional 4,024 shares in the last quarter. 79.48% of the stock is owned by hedge funds and other institutional investors.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total transaction of $1,286,027.50. Following the completion of the transaction, the director now owns 9,250 shares of the company’s stock, valued at $1,286,027.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,227 shares of company stock valued at $2,843,956. Insiders own 0.95% of the company’s stock.

WARNING: This report was reported by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/24/celgene-corporation-celg-shares-bought-by-rafferty-asset-management-llc.html.

A number of equities research analysts have recently weighed in on CELG shares. Cantor Fitzgerald set a $160.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Stifel Nicolaus started coverage on Celgene Corporation in a report on Friday, July 28th. They set a “buy” rating and a $155.00 target price for the company. Canaccord Genuity set a $156.00 target price on Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Cann reissued a “buy” rating and set a $175.00 target price on shares of Celgene Corporation in a report on Tuesday, August 1st. Finally, Jefferies Group LLC reissued a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a report on Monday, July 31st. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $139.57.

Celgene Corporation (NASDAQ:CELG) opened at $105.16 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The company has a market capitalization of $82,794.26, a PE ratio of 16.43, a price-to-earnings-growth ratio of 0.81 and a beta of 1.79. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17.

Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.58 earnings per share. sell-side analysts forecast that Celgene Corporation will post 6.67 EPS for the current year.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.